Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
PALO ALTO, Calif., August 4, 2009 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel
Hepatitis C Virus (HCV) technology from Stanford University. This te...
SENOMYX AND FIRMENICH TO COLLABORATE ON DISCOVERY, DEVELOPMENT AND WORLDWIDE COMMERCIALIZATION OF NOVEL SWEET ENHANCERS
SAN DIEGO, CA AND GENEVA, SWITZERLAND, August 3, 2009 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX ), a leading company focused on using proprietary technologies to discover and develop novel
flavor ingredients for the food, beverage, and ingredient supply indus...
SyntheMed Receives US Patent on Novel Polymer Technology
ISELIN, N.J., July 30 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that it has been awarded US Patent #7,569,643 pertaining to its bioresorbable reverse ...
Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 /PRNewswire/ --
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group
of companies with a focus on the development of prescription drugs that
target unmet medical needs, and MSM Protein Technologies (MSM), a human
OMT announces a breakthrough in the development of a novel human antibody platform
Palo Alto, CA: July 23, 2009 Open Monoclonal Technology, Inc. (OMT), in collaboration with Sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL), The Medical College of Wisconsin, and INSERM, today announced the creation of the first targeted knockout rats as detaile...
Sumavel(TM) DosePro(TM) (sumatriptan injection) Approved by FDA for Acute Migraine and Cluster Headache: First Product Featuring Novel DosePro Needle-Free Delivery System
SAN DIEGO, July 16 /PRNewswire/ -- Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Sumavel DosePro (sumatriptan injection) needle...
Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
BALTIMORE, July 16 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a collaboration with Do-C...
Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
LAGUNA NIGUEL, Calif., July 14 /PRNewswire/ -- Inspiration Biopharmaceuticals today announced the presentation of positive preclinical safety, toxicology and preliminary pharmacokinetic data on its lead product, IB1001, a novel
recombinant Factor IX product to treat patients with he...
EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
EMcision Ltd. today announced clearance for marketing by the United States Food and Drug Administration (K083292) of its Habib™ EndoHPB device for the palliation of biliary and pancreatic tumours.
London (PRWEB) July 14, 2009 -- EMcision Ltd. today announced clear...
Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
Company seeks partner to commercialize the technology
TORONTO, July 9 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (TSX:MBX) announced today that it has filed key patent applications based on its novel
semen sexing discoveries and that it will now embark on the path to commercialization ...
Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd
(Funxional) has announced today the successful completion of the first Phase
I study with FX125L, an orally available small molecule which belongs to a
new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs)....
Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
SAN DIEGO, June 29 /PRNewswire/ -- Palkion, Inc. announced today that it has initiated preclinical development studies for its orally available anemia therapeutic candidate that modulates the Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PH) enzyme system. In February 2008, Palkion was founded ...
Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
OSLO, Norway, June 26 /PRNewswire-FirstCall/ -- Clavis Pharma ASA (OSE:
CLAVIS) today announced that the Company has raised NOK 129 million
(equivalent to USD 20 million) in gross proceeds through a private placement
of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK...
Glenmark's Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
- Melogliptin continues to demonstrate potential to be the
best-in-class in achieving glycemic control with low incidence of
hypoglycemia and neutral effect on body weight
- Global Phase III trials likely to start by end 2009
- IND approved by USFD...
Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
BOSTON, June 11 /PRNewswire/ -- Allied Minds has established SoundCure, Inc. to improve the lives of people suffering from tinnitus (ringing in the ear). Allied Minds, a seed investment corporation specializing in early stage university business ventures, will provide the initial funding and has p...
Calvert Research Licenses Novel Technology to Treat Age Related Macular Degeneration from Tulane University
Calvert Research, LLC (a unit of Calvert Holdings, Inc.) today announced the execution of a license agreement with Tulane University granting Calvert Research (through its wholly owned subsidiary, Calvert T1, LLC) certain rights to issued patents and patent applications covering a technology plat...
Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Company completes initial steps towards producing Influenza A (H1N1) VLP vaccine for animal and human testing
ROCKVILLE, Md., June 4 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) and the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy a...
Biomimetic-engineering design can replace spaghetti tangle of nanotubes in novel material
Nanoelectromechanical systems (NEMS) devices have the potential to revolutionize the world of sensors: motion, chemical, temperature, etc. But taking electromechanical devices from the micro scale down to the nano requires finding a means to dissipate the heat output of this tiny gadgetry.
HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
MedImmune Plans to Begin Shipping Seasonal Vaccine to Health Care Providers in August
GAITHERSBURG, Md., June 1 /PRNewswire/ -- MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has awarded the company a contract to manufacture monovalent (single-strain) l...
ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
HALIFAX, May 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a
vaccine development company, has announced a collaboration agreement with the
National Research Council Institute for Biodiagnostics (NRC-IBD) Atlantic.
This collaboration will develop new 3-D MRI technology to track the e...
ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
HALIFAX, May 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced a collaboration agreement with the National Research Council Institute for Biodiagnostics (NRC-IBD) Atlantic. This collaboration will develop new 3-D MRI technology to track the effec...
New nanotube coating enables novel laser power meter
The U.S. military can now calibrate high-power laser systems, such as those intended to defuse unexploded mines, more quickly and easily thanks to a novel
nanotube-coated power measurement device developed at the National Institute of Standards and Technology (NIST).
The new laser power meter,...
Nano-sandwich triggers novel electron behavior
A material just six atoms thick in which electrons appear to be guided by conflicting laws of physics depending on their direction of travel has been discovered by a team of physicists at the University of California, Davis. Working with computational models, the team has found that the electrons ...
ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
Development Candidate Triggers Milestone Payment from GlaxoSmithKline
MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified an orally bioavailable small molecule antagonist of the C5a receptor, CCX168, as a candidate for clinical ...
Tepha Partner Launches Novel Monofilament Absorbable Suture Utilizing Tepha's Proprietary Biomaterial
Tepha Corporate Partner, Aesculap AG, Introduces MonoMax(R) Monofilament Suture at the German Surgical Congress in Munich following Receipt of CE Mark
LEXINGTON, Mass., May 1 /PRNewswire/ -- Tepha, Inc., a developer of medical devices announced today that its corporate partner, Aesculap A...
PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
ANNAPOLIS, Md., April 28 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a second Phase II study of SparVax(TM) were presented yesterday at the 12th Annual Conf...
Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
Trial Will Evaluate Safety, Proof of Mechanism of a Potential Oral Antagonist for the Treatment of Asthma and COPD
SAN DIEGO, April 20 /PRNewswire/ -- Amira Pharmaceuticals, Inc., announced today the initiation of a Phase I clinical study of AM211, its internally discovered oral drug candidat...
Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies
Centerpiece of the agreement is the establishment of The Waters Centre for BioMedical Mass Spectrometry
MILFORD, Mass., April 15 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) and the University of Warwick , Coventry and Warwickshire, England, today signed a collaborative research ag...
Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
European Trials Commencing for Injectable Biopolymer to Repair Weakened Heart Wall
LAGUNA HILLS, Calif., April 14 /PRNewswire/ -- Symphony Medical, Inc., a developer of novel
biopolymer therapies to cardiac abnormalities, announced today that its patented flagship technology, Algisyl-LVR(R), ...
SeqWright to Invest in LaserGen's Novel Lightning Terminators(TM)
HOUSTON, April 8 /PRNewswire/ -- LaserGen, Inc., a DNA sequencing technology company, announced a definitive agreement in which SeqWright Inc. will make an equity investment in the company. Prompting its decision was LaserGen's recently revealed plans to commercialize its novel
Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
- U.S. FDA approves Intercell's first marketed product, a new vaccine against Japanese Encephalitis for travelers and military personnel
- Commercial product launch in the U.S. planned for Q2 2009
VIENNA, March 30 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that the U.S. Fo...
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales -
- Company to Host Conference Call at 11:00 a.m. ET Today -
EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY ), a mid-stage biopharmaceutical comp...
WaferGen Biosystems, ImmuneRegen BioSciences and University of Texas Southwestern Medical Center to Collaborate on Novel Wound Healing Research
Studies at UT Southwestern to Leverage WaferGen's SmartChip Platform to Evaluate Efficacy of ImmuneRegen's Drug
FREMONT, Calif. and SCOTTSDALE, Ariz., March 24 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic analy...
Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor
Cancer Targeted Therapeutic for Samtheo's Personalized Medicine Portfolio
NEW YORK, March 16 /PRNewswire/ -- Samtheo Biopharma LLC has entered into a license agreement, through its subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, gaining exclusive worldwide rights to a small mo...
InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
- Company Receives Allowance of Patent Claims in the U.S. and in India -
- InNexus Biotechnology CEO Highlighted in Nature Biotechnology -
BRITISH COLUMBIA, Canada, March 6 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsb...
OLIGOMERIX Awarded NIH Grant to Develop Novel Biomarkers for Alzheimer's Disease
NEW YORK, Feb. 25 /PRNewswire/ -- OLIGOMERIX, Inc. today announced the receipt of a Small Business Innovation Research (SBIR) Phase I grant for $323,000 from the National Institute on Aging of the National Institutes of Health (NIH). The focus of the program is to develop novel
biomarker assays fo...
PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
ANNAPOLIS, Md., Feb. 24 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Alternext US: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that results from a Phase II study of SparVax(TM) and pharmacokinetic (PK) data for Valorti...
Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
Claims extend and strengthen Odyssey Thera's coverage to include GPCR directed screening and drug profiling.
SAN RAMON, Calif., Feb. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that it has been granted a United States patent entitled "Fragment Complementation Assays for G-Protein-C...
FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
NERVIANO, Italy, February 10 /PRNewswire/ --
- Nerviano Medical Sciences (NMS): Green Light From the FDA for the CDC7
Nerviano Medical Sciences (NMS) has secured Food and Drug Administration
(FDA) approval to conduct for the first time clinical trials of a novel
IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis
SEATTLE, Jan. 22 /PRNewswire/ -- IDRI (Infectious Disease Research
Institute) announced it has granted the Instituto Butantan, a Brazilian
biomedical research institution, an exclusive license in Latin America and a
non-exclusive license in the rest of the world to use two of IDRI's lead